United BioPharma (UBP), a spinoff company of UBI Asia, was founded by Dr. Chang Yi Wang. Dr. Wang serves as the executive Chairwoman of the Board of Directors and Chief Scientific Officer of UBP. At the invitation of the Taiwanese government in 1998, Dr. Wang set out to establish UBI-Asia, a joint venture between United Biomedical, Inc. (UBI) based in the US and the Taiwan government. She launched a state-of-the-art protein and antibody drug development platform within UBI Asia employing monoclonal antibody B4 as a touch stone and built a competent team with integrated platform technologies to enable development of antibody products from DNA to BLA filings. Other antibody and long acting protein products followed, leading to the spinoff of United Biopharma with a group of rigorously selected antibody products.
Dr. Wang’s invention, UB421, is the first antibody product in UBP’s pipeline. UB421 is an anti CD4 antibody having a unique HIV competitive binding inhibition property. UB421 is currently in multiple Proof of Concept (POC) phase II trials in combination with ART for functional cure, as well as a multinational monotherapy phase III trial for ART substitution. With CD4 being an important immune modulatory molecule, this class of antibodies with characteristic features resembling UB421 have many important first-in-human clinical applications.
In addition to antibody and long acting protein products as biologics for disease treatment, Dr. Wang is a pioneer in using designer synthetic peptides in multiple biomedical applications. Her early inventions in synthetic peptide based HIV and HCV blood screening tests have sold hundreds of millions in the global market; since 2007, her first high precision epitope based vaccine against Foot and Mouth Disease in the animal health field has sold over 4 billion doses in China, the largest global swine market; her second high precision peptide based LHRH targeted immunocastration vaccine has also been launched in the global swine market. These initial inventions have provided UBI with commercialization expertise to become an industry leader in many high precision peptide vaccine applications in disease intervention as immunotherapeutics.
Dr. Wang has received several prestigious awards, including the 2007 Inventor of the Year award from the New York Intellectual Property Law Association (NYIPLA) for her high precision UBITh immunogen designs, and the 2018 Pioneer in Technology Award from the Brain Mapping Foundation for her contribution in the development of vaccines for the treatment of Neurodegenerative Diseases.
Prior to founding UBI in 1985 and its subsequent group of companies to facilitate commercialization of her platform derived inventions, Dr. Wang was a Principal Investigator and director of the Laboratory of Molecular Immunology, endowed by the Arthur J. and Leslie Levine fund, at the Memorial Sloan-Kettering Cancer Center, a faculty member at the Sloan Kettering Institute and an adjunct associate professor at the Cornell University Medical School.
During her research career in the US, she received over US$20 million in grants and contracts from National Institute of Allergy and Infectious Diseases (NIAID) and National Cancer Institute (NCI) of National Institutes of Health (NIH). Dr. Wang has over 120 scientific publications in peer-reviewed high impact journals such as New England Journal of Medicine, Lancet, Science, Journal of Experimental Medicine, and Journal of Infectious Diseases etc. and over 100 issued patents and additional pending patent filings. Dr. Wang received her B.S. in chemistry with honors from National Taiwan University and her Ph.D. in immunology and biochemistry from the Rockefeller University, New York, USA.
Dr. Shugene Lynn is the Chief Executive Officer and a member of the Board of Directors of United BioPharma (UBP). She also serves as a board member of several companies within the UBI group. Prior to joining UBP in January 2019, she was the executive vice president of corporate development at UBI Asia, responsible for corporate strategic planning and financing.
She has been with the UBI group since 1999, beginning as a bench scientist with increasing responsibility from project to program management, to corporate development, and has been associated with every step along the path of UBI growth in Asia. She was the first scientist in the UBI group to be engaged in the antibody humanization platform, and has since led a team to build the therapeutic monoclonal antibody process development platform, and brought the HIV drug candidate UB-421 from cell line development to clinical phase I and II stages. During her tenure at UBI Asia, the company was awarded 11 government research grants, and sponsored three monoclonal antibody drug candidates into clinical trials.
Dr. Lynn received her B.S. in plant pathology and Ph.D. in life sciences from the Institute of Zoology both from National Taiwan University. She completed her postdoctoral training at Academia Sinica and received the Outstanding Postdoctoral Fellow Award in 1998 for her eight first author publications in international journals.
Dr. Liao is currently Executive Vice President of Product Development and a member of the Board of Directors at United BioPharma (UBP). She served as the President of UBP during its formative stage from 2014 to 2018. Dr. Liao has over 35 years’ experience in the biopharmaceutical industry. Prior to joining UBP in January 2014, she was vice president of UBI, responsible for regulatory affairs for biological products and was a key member in UBI’s NIH-funded HIV Therapeutic Vaccine program. From 2003 to 2007, she was vice president of research & development and quality control for Hemispherix Biopharma, Inc., responsible for product development for natural leukocyte interferon (Alferon®) and therapeutic RNA (Ampligen®). She also served from 1983 to 2003 at Interferon Sciences, from a bench scientist with increasing responsibilities to vice president of research and development, where she directed all R&D projects in the major areas of protein biochemistry, cell biology, and molecular biology. Dr. Liao is accomplished in the development of therapeutic biological products, from research to preclinical testing, human clinical trials, and final approval by the US FDA and other regulatory agencies.
She received her B.S. in chemistry from National Tsing Hua University, in Taiwan, her M.S. and Ph.D. in physical biochemistry from Yale University. Dr. Liao completed postdoctoral training at Massachusetts Institute of Technology under the direction of Nobel Laureate Professor H. Gobind Khorana. She is the author of numerous publications and holds several patents in the area of alpha interferons.
Mr. Keith Lau is Chief Financial Officer and Company Secretary at United BioPharma Holdings Co., Ltd; he is Vice President of Finance at United BioPharma Inc. (UBP). Mr. Lau joined United BioPharma from Luoxin Pharmaceutical Group Stock Co. Ltd., where he has served as Financial Controller and Company Secretary.
Mr. Lau’s finance experience includes financial control, auditing, corporate governance, advice on IPO and listed company management. he assisted Luoxin Pharma’s IPO for listing on Hong Kong Exchange in 2003 which was subsequently privatized in 2017. Mr. Lau is also the Independent Non-Executive Director of two listed financial and technology corporations. Earlier in his career, he served as consultant for sizable accounting firm and sponsors for various corporations’ IPO projects.
With an impressive CPA certification from Australia and FCPA from Hong Kong, Mr. Lau has obtained Master of Professional Accounting from Hong Kong Polytechnic University and Bachelors of Commerce from Australian National University
Xingtian Yao is the President of United Biomedical’s Yangzhou subsidiary, the company’s center of excellence base in China for product development and manufacturing.
Prior to joining United Biomedical, Mr. Yao was the chairman and CEO of the Shanghai A Stock Board listed Lian Huan Pharma Inc. which is a subsidiary of Lian Huan Pharma Group of Companies based in Yanzhou. He joined Lian Huan Pharma upon his graduation from China Pharmaceutical University where he earned a BS degree in pharmaceutical science. He began his career at Lian Huan Pharma group in the early 1980’s as a supervisor in a pilot API (Active Pharmaceutical Ingredient) plant, subsequently assuming increasing leadership roles and responsibilities to help with the establishment of many joint ventures and subsidiaries to build the original Lian Huan Pharma company into a group of companies.
During his tenure at Lian Huan Pharma group, he served as vice president and president, taking the role of president of a few affiliates or joint venture entities within the Lian Huan Pharma Group such as Yangzhou Yang-Da Lian Huan Genetic Engineering Ltd., and Shangxi Datong Tongxing Antibiotics Corporation Ltd. In addition, Mr. Yao served as vice president Jiangsu Jinmao Chemistry Pharma group.
In 1995, XingTian received an honorary award from Yangzhou City Government and the Pharmaceutical Industry of the Jiangsu Province as a model employee. Mr. Yao was also a member of the board of directors of Nanking University.